article thumbnail

Kraft Heinz to Remove Artificial Dyes From Products by 2027

Physician's Weekly

products by the end of 2027. government, are now pushing back against them. The post Kraft Heinz to Remove Artificial Dyes From Products by 2027 first appeared on Physician's Weekly. WEDNESDAY, June 18, 2025 (HealthDay News) — One of the nation’s largest food companies is planning a big change to its ingredients list.

article thumbnail

Geriatric Medicine Board Meeting Summary | Spring 2025

ABIM

He emphasized ABIM’s focus on patient-centered standards and promoting high-quality care, as well as ABIM’s commitment to ensuring a diverse governance that reflects the physician and patient population. 4,372 of these (92%) also have a current valid certificate in Internal Medicine.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Governor’s 2025-26 May Revision Proposes Major Cuts to Healthcare and Undermines Medi-Cal Expansion Commitments

California Academy of Family Physicians (CAFP)

Key Health Care Budget Proposals: Proposed Medi-Cal Cuts and Enrollment Changes Medi-Cal, California’s Medicaid program, is typically funded through a partnership between the state and the federal government. To fill that gap, California has chosen to use state-only funds to provide certain Medi-Cal benefits to undocumented Californians.

article thumbnail

MN Legislative Session 2025: Updates on Hearings and Bills

Minnesota Academy of Family Physicians

Key Changes: It implements a base year payment rate structure effective January 1, 2026, which will set specific payment rates for various levels of care, including outpatient and residential treatment services, and mandates annual adjustments based on the Medicare Economic Index, beginning January 1, 2027. Read a summary of HF 1005.

article thumbnail

A Short-Term Gain for a Long-Term Loss? The Build Back Better Act’s Medicare Drug Price Negotiation Program Ignores Hatch-Waxman/BPCIA Realities. and that May Mean Big Bad Business for Generic Drug/Biosimilar Manufacturers

FDA Law

In 2025, the Secretary would select no more than 10, 15 in 2026, 15 in 2027, and 20 in 2028 and subsequent years. There would also be a renegotiation process beginning in 2027 for selected drugs for which factors that the Secretary considered had changed. Let’s put a little more detail on that. That’s a difficult pill to swallow.

article thumbnail

AstraZeneca’s Challenge to Price Negotiation Fails in Federal District Court

FDA Law

In granting the Government’s summary judgment motion, the court held that AstraZeneca did not have the requisite standing for the APA arguments because it failed to identify a cognizable injury-in-fact that could be redressed by vacatur of the Guidance. Opinion at 17. see also 42 U.S.C. 1320f-1(e)(1)(A).

article thumbnail

Update on CDER, CBER, and CDRH Meetings with Industry

FDA Law

The pandemic also deeply impacted how industry and the government conduct their operations. The pandemic had changed the way people live, work and communicate. Such changes are not limited to personal circumstances. One distinct change has been the rise of conducting meetings over digital platforms. However, not all changes are forever.